financetom
Business
financetom
/
Business
/
VinFast's Q3 Results Were 'Big Step in Right Direction,' Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
VinFast's Q3 Results Were 'Big Step in Right Direction,' Wedbush Says
Nov 27, 2024 8:07 AM

10:35 AM EST, 11/27/2024 (MT Newswires) -- VinFast Auto's ( VFS ) Q3 results showed a top-line miss but a bottom-line beat as the company plans to boost deliveries across its entire product line and outperform global rivals, Wedbush said in a report on Wednesday.

VinFast's electric vehicle deliveries of 21,912 were up 66% quarter-on-quarter and E-scooters deliveries of 18,894 increased 44% quarter-on-quarter in Q3 due to "improved reception for VinFast EVs domestically which represents a solid foundation in the space," Wedbush said.

Meanwhile, the company's operating income was "well above" analysts' estimates as its "increasing scale, ongoing BOM and production cost optimization and improved operating efficiencies have already started to have a positive impact on the path to profitability," the note said.

Wedbush analysts said they continue to believe that the carmaker is "in the early innings of a multi-year growth story that is just beginning with facilities expected to open in 2025, an updated portfolio launched for its global customer base, and strict cost management initiatives in place to generate steady profitable growth over the coming years."

Wedbush reiterated an outperform rating and $8 price target.

Price: 3.97, Change: +0.01, Percent Change: +0.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Mar 6, 2024
ViiV Healthcare, majority owned by GSK Plc ( GSK ) , with Pfizer Inc ( PFE ) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial. The data indicated that long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of...
Five9 Insider Sold Shares Worth $2,715,680, According to a Recent SEC Filing
Five9 Insider Sold Shares Worth $2,715,680, According to a Recent SEC Filing
Mar 6, 2024
05:02 PM EST, 03/06/2024 (MT Newswires) -- Michael Burkland, Chief Executive Officer, on March 04, 2024, sold 46,447 shares in Five9 ( FIVN ) for $2,715,680. Following the Form 4 filing with the SEC, Burkland has control over a total of 411,495 shares of the company, with 278,469 shares held directly and 133,026 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1288847/000128884724000020/xslF345X03/wk-form4_1709762280.xml ...
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
Mar 6, 2024
04:42 PM EST, 03/06/2024 (MT Newswires) -- Price: 143.49, Change: +0.47, Percent Change: +0.33 ...
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Mar 6, 2024
Emergent Biosolutions Inc ( EBS ) shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.  The Details: Emergent BioSolutions ( EBS ) reported quarterly losses of 77 cents per share, missing the analyst consensus estimate of losses of 19 cents per share. Quarterly sales came...
Copyright 2023-2026 - www.financetom.com All Rights Reserved